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For decades, a link between increased levels of iron and areas of Alzheimer’s
disease (AD) pathology has been recognized, including AD lesions comprised
of the peptide b-amyloid (Ab). Despite many observations of this association,
the relationship between Ab and iron is poorly understood. Using X-ray
microspectroscopy, X-ray absorption spectroscopy, electron microscopy and
spectrophotometric iron(II) quantification techniques, we examine the inter-
action between Ab(1–42) and synthetic iron(III), reminiscent of ferric iron
stores in the brain. We report Ab to be capable of accumulating iron(III)
within amyloid aggregates, with this process resulting in Ab-mediated
reduction of iron(III) to a redox-active iron(II) phase. Additionally, we show
that the presence of aluminium increases the reductive capacity of Ab,
enabling the redox cycling of the iron. These results demonstrate the ability
of Ab to accumulate iron, offering an explanation for previously observed
local increases in iron concentration associated with AD lesions. Furthermore,
the ability of iron to form redox-active iron phases from ferric precursors
provides an origin both for the redox-active iron previously witnessed in
AD tissue, and the increased levels of oxidative stress characteristic of
AD. These interactions between Ab and iron deliver valuable insights into
the process of AD progression, which may ultimately provide targets for
disease therapies.1. Introduction
Iron is fundamentally involved in multiple processes within the human brain,
including myelin synthesis, neurotransmitter function, along with energy pro-
duction made possible via its ability to change valence states [1,2]. It is this
ability to change valence states however that can also lead to iron toxicity.
Under normal circumstances, iron is stored as ferrihydrite, a redox-inactive
ferric oxyhydroxide within the storage protein ferritin [3]. However, when ferritin
function is compromised, or excess iron concentrations are reached, increased
levels of redox-active labile iron form [4–7]. This labile iron is free to participate
in the Fenton reaction resulting in the generation of reactive oxygen species (ROS)
which go on to induce oxidative stress and neuronal damage [8–11].
Oxidative stress is also a key factor in Alzheimer’s disease (AD), a fatal
neurodegenerative disorder that is characterized by widespread and extensive
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2neuronal death, resulting in memory loss, psychosis and
dementias [5,12,13]. Although not fully understood, it is
becoming accepted that the accumulation of the neurotoxic
peptide b-amyloid (Ab) within neurons is fundamental to
the pathology of AD [14,15]. Ab accumulation leads to its
extracellular deposition, appearing as senile plaques, a hall-
mark lesion of the disease [16,17]. Ab has also been shown
to induce the formation of intracellular neurofibrillary tangles
[18], and it is these manifestations of Ab accumulation that
result in a disruption of energy production, activation of
the immune system and disturbances to normal neuronal
function that ultimately result in cell death [19]. Additionally,
Ab has been shown to be capable of directly inducing the pro-
duction of free radicals, thereby contributing to the oxidative
stress characteristic of the AD brain [20,21].
Since Louis Goodman’s case studies conducted in the
1950s, a link has been suggested between increased regional
brain iron concentrations and areas of AD pathology [22]. Inter-
estingly, increased levels of iron have been shown to exist in
areas of Ab accumulation such a senile plaques and neurofibril-
lary tangles, suggesting that Ab may act as a sink for iron
deposition [22–24]. Further investigations have identified
increased amounts of redox-active iron(II) within AD tissue
[25–32]. The presence of such redox-active iron would rep-
resent a substantial source of ROS production through the
previously mentioned Fenton chemistry [28]. With the accumu-
lation of iron within brain structures, and the occurrence of
oxidative stress being recognized as early stage events in patho-
genesis, the formation of redox-active iron may represent a key
step in the development of the disease [33].
The origin of this redox-active iron is unclear, but it has
been suggested that its formation may be a result of malfunc-
tion in the iron storage protein ferritin, or the interaction of
Ab with poorly liganded, or free iron forms [34]. Recent
findings by Jiang et al. [35] indicate Ab to be capable of
binding to iron, and spectrophotometric studies by Khan
et al. [36] have shown Ab to be capable of reducing iron(III)
to iron(II) phases in solution in vitro. Further to this, electron
tomography studies have revealed the presence of redox-
active iron within senile plaque material taken from the
AD brain [29]. This evidence suggests that Ab may act to
bind natural ferric forms of iron, before chemically reduc-
ing them into pathological ferrous iron phases capable of
inducing oxidative stress. In addition to iron, other metals
such as aluminium, copper and zinc have been shown to
accumulate in areas of AD pathology, with synergies between
these metals possibly altering the mechanisms of Ab/iron
interaction [37,38].
Despite these observations, the relationship between
Ab and iron is poorly understood, and the products of
Ab/iron interaction remain unknown. Here, we use a combi-
nation of methods, including scanning transmission X-ray
microscopy (STXM), X-ray absorption spectroscopy (XAS),
X-ray magnetic circular dichroism (XMCD), transmission
electron microscopy (TEM) and spectrophotometric iron(II)
quantification, to examine the interaction between Ab and
synthetic ferric iron indicative of biological iron forms. More-
over, the effect of the addition of aluminium(III) upon these
processes is assessed.
STXM and XAS are synchrotron-based techniques that
allow the element-specific imaging of a given structure to a
spatial resolution of 20 nm, and the determination of the oxi-
dation state of –3d transition metals in a composite material,respectively. In this study, STXM was used to image the iron
and amyloid content of structures formed following the incu-
bation of Ab with iron(III). Further to this, XAS was used to
detect any changes in the oxidation state of iron when incu-
bated with Ab (either in the presence or the absence of
aluminium) over a 144 h period. XMCD measurements were
used to confirm the oxidation and magnetic state of the iron.
We report Ab to be capable of incorporating and accumu-
lating synthetic iron(III) into aggregate structures, with this
interaction resulting in Ab-mediated chemical reduction of
iron(III) to a pure iron(II) phase. Iron(II) quantification assays
confirmed the reduction of iron(III) by Ab in suspension,
while the addition of aluminium(III) was shown to enhance
the reductive capacity of Ab upon iron and also enabled iron
redox cycling. Taken together these results offer an explanation
for the increased iron levels witnessed in areas of AD pathol-
ogy, and also suggest an origin for the redox-active iron
forms and oxidative stress previously witnessed in AD tissue,
thereby shedding light on the process of AD pathogenesis.2. Material and methods
2.1. Scanning transmission X-ray microscopy and
transmission electron microscopy
Element-specific images revealing the structure and composition
of Ab/iron(III) aggregates with a spatial resolution of approxi-
mately 20 nm were obtained by performing STXM on the
PolLux beamline at the Swiss Light Source (Paul Scherrer Insti-
tute, Switzerland). TEM was performed using a JEOL 1230
microscope operating at 100 kV. Where both STXM and TEM
were employed on the same sample membrane, the STXM
measurements were performed first to exclude the effect of
electron beam damage to the aggregates.
2.1.1. Preparation of samples
Frozen Ab(1–42) (Bachem) was thawed and dissolved in 0.1 M
sodium hydroxide (NaOH) to create a 1 mgml–1 (220 mM)
stock. NaOH was used to dissolve any insoluble Ab aggregates
that may have formed during peptide storage, thereby reverting
amyloid aggregation (as recommended by the peptide manufac-
turer). The Ab stock was left at room temperature for 30 min
to ensure complete peptide dissolution before being immedia-
tely added to modified Krebs–Henseleit (KH) buffer (pH 7.4;
100 mM PIPES). Two amyloid treatments were prepared. (i) To
assess the co-aggregation of Ab and iron, 18 mM iron(III) nitrate
solution was added to KH buffer immediately after Ab and
the resulting Ab/iron(III) hydroxide suspensions were left to
incubate at 378C for 96 h before sampling. (ii) In order to inves-
tigate the inclusion of iron into pre-formed Ab structures, Ab
solutions in KH buffer were allowed to incubate for 48 h at
378C before the addition of 18 mM iron(III) nitrate solution. Fol-
lowing the addition of iron(III), Ab/iron(III) suspensions were
allowed to incubate for a further 30 min before sampling. For
both Ab/iron preparations, final peptide and iron concentrations
were 35 and 370 mM, respectively.
Small volumes (15 ml) of Ab/iron(III) hydroxide suspensions
were deposited onto silicon nitrate membranes (75 nm thick-
ness, DuneSciences), and excess liquid removed with filter
paper to prevent any artefacts arising due to the drying of
the suspensions. The membranes used were pre-treated with a
hydrophilic compound to encourage the deposition of Ab/
iron(III) structures onto the membrane windows. Following
sample deposition, the silicon membranes were loaded onto
aluminium plates for STXM examination.
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32.1.2. Scanning transmission X-ray microscopy analysis
Carbon maps revealing the amyloid structure of Ab/iron aggre-
gates were created by performing raster scans across Ab/iron
structures at the peak carbon K-edge energy (288 eV) and off-
peak energy (282 eV). Scans at multiple energies across the
carbon K-edge (280–320 eV) were performed across the Ab/iron
aggregates in order to determine the X-ray absorption spectrum
characteristic of Ab. Maps showing the iron content of Ab struc-
tures were created by conducting scans at the iron L3 peak energy
(710 eV) and off-peak energy (705 eV), with differences in these
scans providing the location of any iron within the Ab aggregates.
As the absorbance energies of iron are higher than those of carbon,
STXM carbon analysis of Ab structures was conducted prior to
analysis of the iron content, in order to minimize X-ray-induced
damage to the amyloid structure. Interface
11:201401652.2. X-ray absorption spectroscopy and iron(II)
quantification in suspension
2.2.1. Preparation of iron/amyloid suspensions
Iron(III) hydroxide suspensions were prepared by diluting
18 mM iron(III) nitrate (Sigma-Aldrich) in deionized water and
subsequently neutralizing to pH 7 with 1 M NaOH, giving
an iron concentration of 440 mM. Suspensions containing both
440 mM iron(III) and 440 mM aluminium(III) at pH 7 were cre-
ated from 18 mM iron(III) nitrate, and 37 mM aluminium(III)
nitrate (Perkin-Elmer) in a similar manner as described above,
with aluminium(III) nitrate being added after the iron(III) nitrate.
All suspensions were sonicated for 5 min prior to Ab addition to
encourage a homogeneous metal distribution.
Frozen Ab(1–42) was thawed and dissolved in 0.1 M NaOH
to create a 1 mg ml21 (220 mM) Ab stock. This Ab stock was
allowed to sit for 30 min to ensure complete peptide dissolution
before being added to the previously prepared metal suspen-
sions. Ab/metal suspensions were again neutralized to pH 7
following the addition of the Ab stock, via the addition of
0.1 M hydrochloric acid (HCl). Final Ab and metal concen-
trations were 35 and 370 mM, respectively. Amyloid-free iron
suspensions were created in the same manner as above with
the substitution of deionized water in place of Ab. All Ab/iron
suspensions and amyloid-free controls were incubated at 378C
over a period of 144 h.2.2.2. X-ray absorption and X-ray magnetic circular dichroism
spectroscopy
Small volumes (15 ml) of the Ab/metal suspensions and their
Ab-free controls were pipetted onto carbon/formvar-coated
copper TEM grids (200 mesh; Agar Scientific), and excess liquid
removed using filter paper. Sampling was performed after
30 min, 48 h and 144 h of metal incubation with Ab. The grids
were then mounted onto copper plates for X-ray absorption (XAS
and XMCD) examination. These samples were kept under anoxic
conditions throughout the experimental process to prevent any
changes in ironvalence chemistry (see the electronic supplementary
material for more information regarding anoxic methodology).
XAS and XMCD measurements were conducted on beamline
4.0.2 at the Advanced Light Source (Berkeley Laboratory, USA)
and beamline I10 at the Diamond Light Source (Oxfordshire,
UK). Prior to spectra acquisition, two-dimensional maps at a
spatial resolution of 100 mm revealing areas of iron accumulation
within the sample area were created by raster scanning across the
sample grid at the iron L3 absorption peak energy (710 eV) and
off-peak energy (705 eV; see the electronic supplementary
material, figure S1). Differences in these maps revealed areas
containing substantial iron deposition. Detailed XAS/XMCD
scans were then performed on these areas of iron accumulationacross the entire iron L2,3 absorption edge (700–740 eV), provid-
ing information regarding both the oxidation state and the
magnetic properties of the iron. However, not all iron deposits
located in this way provided a sufficiently stable signal for full
XAS/XMCD analysis to be performed.
The X-ray absorption (XAS) spectra, revealing the oxidation
state of iron in the samples, were recorded using the total elec-
tron yield method, while the magnetic properties were probed
by analysing XMCD spectra. The latter were obtained by
measuring the difference in X-ray absorption using circularly
polarized X-rays, when a 0.6 T magnetic field was applied in
opposing orientations along the X-ray beam direction.
2.3. Iron(II) quantification in suspension: Ferrozine assay
Spectrophotometric determination of the iron(II) content of Ab/
iron(III) hydroxide suspensions was achieved by performing a
Ferrozine iron(II) colorimetric quantification assay. Ferrozine is a
compound that selectively binds to iron(II) ions in solution/
suspension, causing the formation of a stable magenta complex
that absorbs light at a wavelength of 562 nm [39]. The degree of
this colour change is directly correlated to the amount of iron(II)
present upon Ferrozine addition, and therefore can be used to
assess the iron(II) content of a given solution/suspension.
To assess the iron(II) content of the Ab/metal suspensions,
small volumes of sample were removed and digested in 0.5 M
HCl for 3 h at room temperature to release any bound iron
from Ab structures in order to enable Ferrozine binding. Acid-
digested samples were then added to 2 mM Ferrozine, and
absorbance read at 562 nm. The total iron content of the Ab/
metal suspensions was recorded by adding small volumes of
the sample solution to 0.5 M HCl and 6.25 M hydroxylamine
hydrochloride (an iron-reducing agent), at room temperature
for 3 h. These reduced samples were then added to 2 mM Ferro-
zine and absorbance read at 562 nm as before. From these
measurements, the iron(II) content as a percentage of total iron
content was determined. The iron(II) contents of Ab-free iron
controls were assessed in the same way to provide iron(II)
background levels for all iron suspensions used.
Spectrophotometric measurements were performed as des-
cribed above on samples taken after 0, 24, 48, 72, 120 and 144 h
of metal incubation with Ab. No iron(II) quantification data were
collected after 96 h of incubation owing to the limited amount of
sample volume available.
2.4. Statistical analysis
Statistical analysis of the data obtained from iron(II) quantifi-
cation in suspension was performed using a one-way analysis
of variance (GraphPad PRISM 6). This is a method of comparing
sample means for two or more populations. The null hypothesis
of equal means was rejected at the 5% confidence level.3. Results
3.1. The co-aggregation of iron and Ab(1–42)
TEMexamination of amyloid structures incubatedwith iron(III)
revealed the formation of fibrillar aggregates ranging from
1 to 50 mm in size and containing electron dense regions, typical
examples of which are shown in figure 1. No obvious corre-
lation between incubation time and aggregate size could be
determined in these samples with both smaller (less than
5 mm) aggregates, and thick electron opaque regions (not
shown) seen in many of the samples. In addition, it was
observed that dense precipitates could be found in aggregates
after only 30 min incubation (figure 1).
(a)
1 mm 1 mm
2 mm 2 mm
(b)
Figure 1. TEM images of typical Ab structures formed following (a) 0.5 and (b) 96 h of Ab incubation with iron(III).
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Figure 2. STXM images and carbon K-edge spectra of an Ab/iron aggregate formed following 96 h of Ab/iron(III) incubation. (a) Carbon map showing the Ab
structure of the aggregate. (b) Iron map revealing the iron content of the aggregate. (c) Carbon/iron composite image displaying both the Ab (cyan) and iron (red)
content shown in (a) and (b), respectively. (d ) Calculated (blue) and experimental (red) carbon K-edge spectra for Ab. The calculated spectrum was obtained using
the procedures described by Stewart-Ornstein et al. [40].
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4To investigate the nature of the electron dense regions in the
aggregates, STXM was performed. Where Ab and iron(III)
were added simultaneously and allowed to incubate for 96 h,
carbon K-edge mapping of aggregates showed evidence of
fine structure similar to that observed by TEM, together with
dense carbon containing regions (figure 2a).
Examination of the X-ray absorption by the aggregates
across the entire carbon K-edge (280–320 eV) revealed spectra
consistent with the calculated carbon spectrum for the amino
acid sequence of the Ab(1–42) peptide, confirming theamyloid content of the aggregates (figure 2d ). Characteristic
features of the peptide spectrum are a low energy peak
(labelled 1, figure 2d ) which arises from the aromatic amino
acids, the dominant p* amide peak (labelled 2) and a
weaker shoulder feature (labelled 3) associated with arginine
[40]. Iron L-edge examination of the same aggregates showed
regions of iron accumulation within the amyloid structure,
indicating the co-aggregation of iron with Ab (figure 2b).
Iron was found to possess a fine structure similar to the amy-
loid, and regions of dense iron were contained within the
(c)
(b)
(e)
(e)
(d)
(a)
2 mm
1 mm
1 mm
2 mm
2 mm
(d )
Figure 3. STXM and TEM images of an Ab/iron aggregate formed following
96 h of Ab/iron(III) incubation. (a) Carbon map showing the Ab structure of
the aggregate. (b) Iron map displaying the iron content of the same aggre-
gate. (c) Carbon/iron composite image displaying both the Ab (cyan) and
iron (red) content shown in (a) and (b), respectively. (d,e) TEM images of
the Ab aggregate as labelled in (c).
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5aggregates (figure 2c). A comparison of aggregates measured
by both STXM and TEM showed that many of the dense
regions seen by TEM were owing to accumulated iron
within the aggregate (figure 3). However, no evidence of
similar iron accumulation was observed in the absence of Ab.
CarbonK-edge and iron L-edge examination of Ab samples
allowed to incubate in KH buffer for 48 h prior to the addition
of iron(III) led to the observation of Ab structures indis-
tinguishable from those formed where Ab and iron(III) were
added simultaneously (figure 4a). Combined STXM and TEM
images of these aggregates showed them to be fibrillar
in nature containing multiple areas of iron accumulation
(figure 4), suggesting iron had incorporated into Ab structures
that had formed prior to the addition of the metal.
3.2. Oxidation state of iron, following Ab interaction
3.2.1 Iron(III) series
Iron L2,3 X-ray absorption spectra obtained from iron(III)
samples maintained under anoxic conditions both in the
absence and the presence of Ab are shown as a function of
time in figure 5. Pure iron(III) minerals provide X-ray absorp-
tion spectra comprised of a low energy L3 shoulder feature at
708 eV, followed by a dominant peak at 709.5 eV arising from
the presence of Fe3þ cations (see, for example, the reference iro-
n(III) (FeO(OH)) spectrum in figure 6). As the low energy
spectral feature of iron(III) minerals is located at the same
energy point (708 eV) as the peak from Fe2þ cations, increases
in the iron(II) content of a given iron mineral appear to cause
an enhancement in this 708 eV feature.
Where iron(III) was incubated in the absence of Ab, the XAS
spectra obtained were seen to resemble that of iron(III)references, but with slightly enhanced Fe2þ features (figure 5a).
As the iron forms used for this experiment were amorphous in
nature, this enhancement in iron(II) content is believed to be a
result of X-ray beam exposure (in contrast to more crystalline
iron forms such as magnetite which are stable under X-ray
beam exposure). However despite this initial X-ray beam
reduction, further X-ray exposure was not sufficient to form a
pure iron(II) phase (see the electronic supplementary material,
figure S2).
Where Ab was incubated with iron(III) for 30 min, it was
not possible to obtain a sufficient signal for reliable XAS and
XMCD measurements. However, following 48 h of incu-
bation with Ab, iron was found to be in a predominantly
Fe(III) phase (figure 5b), although clear evidence of enhanced
Fe2þ cation features were apparent at 708 eV. This moderate
reduction effect is again believed to be a result of X-ray
beam exposure, as progressive reduction was seen with
increasing periods of beam exposure (see the electronic sup-
plementary material for an example of consecutive XAS
measurements of an unstable iron form).
After 144 h of Ab/iron incubation, iron was found to be
reduced to a pure iron(II) phase (figure 5b) with a Fe2þ
cation dominated XAS spectrum (for reference iron(II) spec-
tra, see iron chloride (FeCl2) spectrum in figure 6). The Fe
2þ
cation peak at 708 eV is seen to be dominant, with the Fe3þ
features at 709.5 eV having disappeared. This reduction
effect was mirrored at the iron L2-edge (720–725 eV). As
such pure iron(II) phases could not be formed in the absence
of Ab, the occurrence of this iron(II) mineral appears to be as
a result of Ab interaction with iron(III).3.2.2. Iron(III) and aluminium(III) series
Iron L2,3 X-ray absorption spectra obtained from iron(III)
hydroxide suspensions when incubated with aluminium(III)
in the presence and the absence of Ab are shown in figure 7.
In the absence of Ab, no evidence of a pure iron(II) mineral
was found at any of the time points examined (figure 7a).
Iron regions located after 144 h of incubation (figure 7a)
show an iron L-edge spectra characteristic of a pure iron(III)
mineral. However, reduced iron can be seen in the Ab-free
control sample after 30 min of incubation, manifesting as an
enhancement in the shoulder at 708 eV. As for previously
described results, this increase in Fe2þ cation peak intensity
is thought to be owing to reduction caused by exposure to
the X-ray beam. Despite this initial X-ray-mediated reduction,
extensive periods of X-ray beam exposure did not lead to the
formation of a pure iron(II) phase.
After 48 h of iron(III) incubation with Ab and alu-
minium(III), iron L2,3 X-ray absorption spectra of Ab/iron
aggregates (figure 7b) resembled that of a pure iron(II)
phase (figure 6). The L3 iron(II) peak at 708 eV had become
dominant with the L3 iron(III) peak at 709.5 eV having disap-
peared. This pure iron(II) form was very similar to that seen
after 144 h of Ab/iron incubation in the absence of alu-
minium (figure 5b), indicating that a similar reduced iron
phase had been formed but over a shorter incubation time.
However, this pure iron(II) phase was not maintained after
144 h incubation, with iron reverting back to a largely iron(III)
phase with some evidence of a Fe2þ cation content (figure 7b).
This subsequent oxidation of the pure iron(II) phase for longer
incubation times may indicate the establishment of an iron
redox cycle.
(a) (b)
(c)
(b)
(c)
5 mm 2 mm
2 mm
Figure 4. STXM and TEM images of a Ab aggregate allowed to incubate for 48 h prior to the addition of iron(III). (a) A composite image showing the Ab (cyan)
and iron (red) content of the Ab/iron aggregate. TEM images showing the fibrillar structure of the Ab/iron aggregate in areas of high (b) and low (c) iron content
as displayed in (a).
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Figure 5. Iron L-edge X-ray absorption spectra of iron(III) in the absence (a) and
presence (b) of Ab after 48 and 144 h of incubation. Grey dashed line at 708 eV
in (b) provides a visual guide for iron(II) content. (Online version in colour.)
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Figure 6. Reference iron L-edge X-ray absorption spectra for iron(III)
(FeO(OH)) and iron(II) (FeCl2). The iron L2 and L3 regions are labelled for
FeO(OH). (Online version in colour.)
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63.3. Oxidative state of iron in suspension following Ab
interaction
To further investigate the reduction of iron(III) by Ab in sus-
pension, a spectrophotometric iron(II) quantification assay
was performed. The iron(II) contents of suspensions contain-
ing Ab and iron(III); Ab, iron(III) and aluminium(III); and
their Ab-free controls are shown in figure 8a,b, and respective
control corrected iron(II) contents are shown in figure 8c,d.The iron(II) content of all Ab-free suspensions was
found to remain consistently low throughout all time
points examined (figure 8a,b) with no clear evidence of
iron(II) reduction being apparent. Where iron(III) was incu-
bated with Ab, no significant increases in control corrected
iron(II) content were seen at the 0, 24 or 48 h time points
(figure 8c). After 72 h, iron(II) content had risen to 4% and
continued to rise to 9% at the 120 h time point and 15%
after 144 h. Although iron(III) reduction by Ab is evidenced,
redox cycling was not apparent within this time frame, an
observation consistent with X-ray absorption measurements
(figure 5b).
In iron(III) suspensions containing Ab and aluminium(III)
an immediate conversion of iron(III) to iron(II) was observed,
with control corrected iron(II) content accounting for 16% of
the total iron content at time zero (figure 8d ). Iron(II) levels
then dropped to 12% after 24 h, before rising to 19% after
48 h incubation. This cycling of iron(II) continued, with
iron(II) content disappearing entirely after 72 h incubation,
before increasing to 25% and 42% of total iron content after
120 and 144 h, respectively.
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Figure 7. Iron L-edge X-ray absorption spectra for iron(III) aggregates contain-
ing aluminium(III) in the absence (a) and the presence (b) of Ab. Incubation
times are indicated above spectra. The grey dashed line at 708 eV in (b) is a
visual indicator for iron(II) content. (Online version in colour.)
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7These results show the reduction of iron(III) by Ab in
suspension, a result consistent with data collected via XAS
(figures 5 and 7). The addition of aluminium appears to
have a catalytic effect on iron reduction by Ab, while also
acting to increase the reductive capacity of Ab, enabling the
redox cycling of iron.
3.4. Magnetic state of iron following Ab interaction
XMCD measurements were conducted across the iron L2,3
absorption edges of the samples in order to examine the
magnetic state of the material present. Magnetic iron oxides
such as magnetite (Fe3O4) generate a strong XMCD effect
of 10–15%. This XMCD profile (figure 9a) appears as three
peaks across the iron L3 region as a result of Fe
2þ and Fe3þ
cations occupying tetrahedral and octahedral crystal sites [42].
For titanomagnetite (figure 9b), an additional low energy posi-
tive peak is observed corresponding to Fe2þ cations occupying
tetrahedral crystal sites [41]. The oxidation state of the mineral
determines the relative intensities of these peaks, with oxida-
tion causing an increase in Fe3þ cation intensity with respect
to the Fe2þ cation peaks, and reduction causing an increase in
the Fe2þ cation component with respect to the Fe3þ.
Iron L2,3 absorption-edge XMCD examination of iron(III)
and aluminium(III) either in the presence or the absence
of Ab produced spectra with no evidence of strongly mag-
netic material. Instead a weak magnetic signal of 1–1.5%
was observed throughout all samples examined (figures 10
and 11). Ab-free iron(III) and aluminium(III) samples pro-
duced spectra comprised of two positive and two negativepeaks (figure 10a (red); peaks A–D). By comparison with
XMCD spectra obtained from titanomagnetite [41], these
peaks appear to arise from the presence of both Fe2þ cations
(figure 9b, peaks A and B) and Fe3þ cations (peaks C and D)
that occupy tetrahedral and octahedral crystal sites.
The relative intensities of the peaks A–D shown in figure 9
reflect the oxidation state of magnetic Fe cations. XMCD exam-
ination of the pure iron(II) phase formed after 48 h of Ab
incubation with iron(III) and aluminium(III) showed dramatic
enhancement of the Fe2þ cation features, with no evidence
of Fe3þ cations on either the tetrahedral or octahedral sites
being apparent (figure 10b). This XMCD signal is consistent
with the formation of a weakly magnetic pure iron(II) phase.
Subsequent oxidation after 144 h incubation can be seen as
an increase in the Fe3þ cation XMCD features (figure 10b),
mirroring the behaviour seen in the XAS spectra (figure 7b).
XMCDspectra obtained from thepure iron(II) phase formed
following 144 h of incubation of Ab with iron(III) (figure 11)
were identical to those measured fromAb incubations contain-
ing both iron(III) and aluminium(III) (figure 10b), suggesting a
similar weakly magnetic iron(II) phase to have been formed,
but over a longer period of time.
It should be noted that some distortions to the XMCD
peak intensities are apparent owing to background X-ray
absorption drift, resulting in a negative or positive slope
across the XMCD profile (figure 10a (blue) and b (red)). How-
ever, despite these distortions, the overall trend of the XMCD
spectra remains correct.4. Discussion
Through the use of multiple techniques, including STXM,
electron microscopy, XAS and spectrophotometric iron(II)
quantification, it was found that the AD peptide Ab(1–42)
is capable of incorporating iron(III) minerals into fibrillar
aggregate structures in vitro, with this interaction leading to
the chemical reduction of iron(III) into a pure iron(II) phase.
Microspectroscopy (STXM) and TEM images of structures
formed following the incubation of Ab with iron(III) revealed
the presence of large fibrillar amyloid aggregates containing
multiple areas of iron accumulation. As amyloid and iron
morphology were found to be closely correlated and iron
was only observed when co-precipitated with Ab, these data
suggest that Ab acts to accumulate iron within its structure
with possible binding of iron occurring almost immediately
(after 30 min incubation). This effect did not appear to be
dependent upon the aggregation state of amyloid, with iron
accumulation within Ab aggregates occurring where iron(III)
was added to pre-formed amyloid aggregates. These findings
are in agreement with those published by Jiang et al. [35],
who suggested Ab to act as a metalloprotein capable of
binding to iron.
The iron accumulation into amyloid aggregates that we
have observed here could also provide an explanation for
the increased concentrations of iron previously witnessed in
AD plaque material [24]. With iron levels being shown to be
increased in the AD brain [4,10,22,43], it is entirely feasible
that Ab acts to draw iron into its structure, where it then
binds to the metal. Such a process would explain observations
made by Lovell et al. [24], who used micro particle-induced X-
ray emission analysis to show increased iron levels to exist
within senile plaque material compared with surrounding
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8brain tissue, and by Meadowcroft et al. [44], who used mag-
netic resonance imaging to show the accumulation of iron
within Ab plaques. Further to this, the ability of iron to bind
to amyloid provides an explanation for the increased iron
levels corresponding to areas of AD pathology as witnessed
in mice overexpressing Ab [45].
XAS examination of Ab/iron(III) precipitates revealed the
formation of a pure iron(II) mineral following prolonged
periods (144 h) of Ab/iron interaction. Such data show Ab
to be capable of directly reducing synthetic iron(III) in the
absence of any other influencing factors. Further evidence
of iron reduction by Ab was provided via iron(II) quantifi-
cation in suspension, where 15% of the total iron content
was found to be in an iron(II) state when incubated following
144 h of Ab/iron incubation. These results are consistent
with our previous work where we found Ab induced the
reduction of the iron(III) oxyhydroxide mineral ferrihydrite
[46]. The formation of pure iron(II) forms suggests Ab to
possess a strong reducing capacity upon iron, a result consist-
ent with Khan et al. [36], who showed Ab-mediated iron(III)
reduction via spectrophotometric methods. These observa-
tions, combined with the previously stated STXM and TEM
findings, indicate that Ab acts to accumulate iron within its
fibril structure with this interaction (binding) leading to Ab-
mediated iron reduction following prolonged periods of
contact. This Ab-induced iron reduction is expected to result
in the oxidation of Ab and the generation of ROS as described
by Huang et al. [11]. However, limitations of the methodology
used here prevented these reaction mechanisms from being
confirmed in this study.
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9XAS examination of Ab aggregates containing both
iron(III) and aluminium(III) led to the observation of a simi-
lar pure iron(II) phase, but formed over a shorter interaction
time (48 h) than where aluminium was absent. This catalytic
effect of aluminium upon Ab iron reduction was confirmed
by iron(II) quantification assay, with the addition of alu-
minium leading to higher levels of iron reduction. Both
XAS and iron(II) quantification assays revealed evidence
of iron redox cycling where aluminium(III) was added to
Ab/iron(III) incubations, whereas no evidence of redox
cycling was seen in its absence. These results show alu-
minium to act as an effective catalyst for the interaction of
iron with Ab, enabling the redox cycling of iron over the
time period examined. These findings are also consistentwith the work of Khan et al. [36], who show Ab to be capable
of inducing the redox cycling of iron, with the presence
of aluminium(III) appearing to potentiate the reduction of
iron(III) to iron(II); and also recent investigations by Ruiperez
et al. [47], who show aluminium to promote the Fenton
reaction by aiding the reduction of iron(III) to iron(II) [47].
The ability of Ab to form iron(II) phases from iron precur-
sors reminiscent of naturally occurring ferric iron provides a
possible origin for the redox-active iron forms previously
seen within AD tissue, such as the increased levels of the
iron(II)-rich minerals magnetite and wu¨stite witnessed in
pathological ferritin cores by Quintana et al. [27], along
with the accumulation of magnetite-like material within AD
plaque cores as observed by Collingwood et al. [29]. How-
ever, in contrast to our previous study on the interaction of
Ab with ferrihydrite [46], here we found no clear evidence
for the formation of crystalline iron minerals as indicated
by electron diffraction patterns.
XMCD analysis of the magnetic state of iron in samples
prepared from both amyloid incubations and amyloid-free
controls revealed iron cations in different crystal symmetry
sites reminiscent of octahedral and tetrahedral coordination.
This result was also found previously for ferrihydrite iron
deposits [46] and thus appears to be a common feature of
amorphous or nanocrystalline iron oxyhdroxides. The pure
iron(II) phases observed by XAS, formed both with and with-
out aluminium, were found by XMCD to contain Fe2þ cations
arranged with opposing magnetic orientations. This implies
the presence of antiferromagnetic coupling between Fe2þ
cations on different crystal symmetry sites. These pure
iron(II) phases could therefore represent an amorphous precur-
sor for an antiferromagnetic iron(II) mineral such as wu¨stite.
rsif.royalsocietypublishing.org
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105. Conclusion
From this study, it is apparent that Ab is capable of interacting
with iron in a manner that leads to the accumulation and
co-aggregation of iron within Ab structures, resulting in the
chemical reduction of redox-inactive ferric iron to a redox-
active ferrous iron form. With iron being abundant throughout
brain tissues [1], and iron being shown to be increased in areas
of AD pathology (in both human post-mortem tissue and AD
transgenic models) [22,24,45], the ability of Ab to induce the
formation of redox-active iron(II) minerals from ferric precur-
sors would represent a significant and sustained source of
ROS capable of inducing widespread neuronal damage. The
interaction of Ab with iron could thus be an important contri-
butor to the oxidative stress characteristic of AD, thereby
playing a key role in the pathogenesis of the disorder. Further-
more, the apparent ability of Ab to reduce iron(III) to an
iron(II) phase even when iron is present in a 10 : 1 excess
of Ab strongly suggests that Ab is an efficient biological
iron-reducing agent. The catalytic function of aluminium(III)
upon Ab-mediated iron reduction as witnessed in this study
is also of vital importance. With aluminium being implicated
as a promoting factor for the development of AD, any syner-
gies existing between Ab, iron and aluminium are likely to
influence the nature of AD progression [48]. Interestingly,
redox-active iron has also been identified within rat microglia
following kainate-induced neuronal injury. These findings
indicate towards amyloid-independent sources of ferrous
iron in the degenerating brain, which could further contribute
to iron-induced toxicity within AD tissues [49].As pure iron(II) phases do not occur naturally [27,50], these
pathological iron biominerals may represent a target for future
therapies. Removal of such forms of iron, or disruption in the
ability of Ab to interact with iron, may result in a reduction of
the free radical burden associated with the AD brain and con-
sequently a slowing of disease progression. The addition of
aluminium appears to impact the reductive capacity of Ab
by increasing its ability to reduce iron(III) in suspension. Alu-
minium is also not naturally found within human tissues [51],
and therefore its removal from brain tissue may act to reduce
Ab neurotoxicity, while not impacting healthy brain functions.
In summary, key insights into the relationship between Ab
and iron have been made that provide valuable insights into
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